14,031 Shares in Altimmune, Inc. (NASDAQ:ALT) Purchased by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP bought a new stake in shares of Altimmune, Inc. (NASDAQ:ALT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 14,031 shares of the company’s stock, valued at approximately $101,000.

A number of other hedge funds have also recently modified their holdings of ALT. Wells Fargo & Company MN increased its stake in Altimmune by 69.3% in the fourth quarter. Wells Fargo & Company MN now owns 215,538 shares of the company’s stock worth $1,554,000 after purchasing an additional 88,209 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of Altimmune in the fourth quarter worth about $45,000. Marshall Wace LLP bought a new position in shares of Altimmune in the fourth quarter worth about $472,000. Bellevue Group AG increased its stake in Altimmune by 9.5% in the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock worth $6,817,000 after buying an additional 81,786 shares during the period. Finally, Invesco Ltd. lifted its holdings in Altimmune by 679.2% during the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company’s stock valued at $1,781,000 after buying an additional 215,375 shares in the last quarter. Institutional investors own 78.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on ALT shares. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday, April 3rd. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $20.20.

Insider Transactions at Altimmune

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Altimmune Stock Performance

Shares of ALT opened at $6.01 on Tuesday. The stock has a 50-day moving average of $5.09 and a two-hundred day moving average of $6.60. The stock has a market cap of $462.85 million, a P/E ratio of -3.88 and a beta of 1.13. Altimmune, Inc. has a one year low of $3.55 and a one year high of $11.16.

Altimmune (NASDAQ:ALT) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. Analysts predict that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.